5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy

Biochimica et Biophysica Acta - Biomembranes

Volumn 1848, Issue 10, 2015, Pages 2738-2746

  Navari, Rudolph M ^a,b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT3 receptor antagonists; Antiemetics; Chemotherapy induced nausea and vomiting; Serotonin

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AZASETRON; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANISETRON; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; METOCLOPRAMIDE; MITOXANTRONE; NAVELBINE; OLANZAPINE; ONDANSETRON; OXALIPLATIN; PHENOTHIAZINE; SEROTONIN 3 RECEPTOR; UNINDEXED DRUG; VINBLASTINE; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; ISOQUINOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; PALONOSETRON; QUINUCLIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ACUTE CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; ANTICIPATORY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; ARTICLE; BREAKTHROUGH CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; SYSTEMATIC REVIEW (TOPIC); CHEMICALLY INDUCED; HALF LIFE TIME; METABOLISM; NAUSEA; NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; DEXAMETHASONE; HALF-LIFE; HUMANS; ISOQUINOLINES; NAUSEA; NEOPLASMS; NEUROKININ-1 RECEPTOR ANTAGONISTS; QUALITY OF LIFE; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84941263096     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2015.03.020     Document Type: Article

References (68)

1. B. Bloechl-Daum, R.R. Deuson, P. Mavros, and et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment J. Clin. Oncol. 24 2006 4472 4478
2. R.M. Navari Management of chemotherapy-induced nausea and vomiting. Focus on newer agents and new uses for older agents Drugs 73 2013 249 262
3. W.D. Miner, G.J. Sanger, and D.H. Turner Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis Br. J. Cancer 56 1987 159 162
4. R.M. Navari Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer Future Oncol. 6 2010 1074 1084
5. R.M. Navari The current status of the use of palonosetron Expert. Opin. Pharmacother. 14 2013 1281 1284
6. M.P. Curran, and D.M. Robinson Aprepitant: a review of its use in the prevention of nausea and vomiting Drugs 69 2009 1853 1858
7. R.M. Navari Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting Eur. J. Pharmcol. 722 2014 180 186
8. L. Tan, J. Liu, X. Liu, and et al. Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting J. Exp. Clin. Cancer Res. 28 2009 1 7
9. R.M. Navari, S.E. Gray, and A.C. Kerr Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial J. Support. Oncol. 9 2011 188 195
10. R.M. Navari Treatment of chemotherapy-induced nausea Community Oncol. 9 2012 20 26
11. R.M. Stern, K.L. Koch, and P.L.R. Andrews Nausea: mechanisms and management 2011 Oxford University Press New York
12. F. Roila, J. Herrstedt, M. Aapro, and et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann. Oncol. 21 5 2010 232 243
13. E. Basch, A.A. Prestrud, P.J. Hesketh, and et al. Antiemetic American Society Clinical Oncology clinical practice guideline update J. Clin. Oncol. 29 2011 4189 4198
14. NCCN Clinical Practice Guidelines in Oncology version 2.2014; Antiemesis. National Comprehensive Cancer Network (NCCN) [online] Available from URL: http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf (Accessed 2014 July 08)
15. T. Koga, and H. Fukuda Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs Neurosci. Res. 14 1992 366 379
16. B.J. Yates, L. Grelot, I.A. Kerman, and et al. Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem Am. J. Physiol. 267 1994 R974 R983
17. R.M. Navari Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents J. Support. Oncol. 1 2003 89 103
18. P.J. Hesketh New treatment options for chemotherapy-induced nausea and vomiting Support. Care Cancer 12 2004 550 554
19. K. Simpson, C.M. Spencer, and K.J. McClellan Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting Drugs 59 2000 1297 1315
20. E. Kimura, E. Niimi, A. Watanabe, and et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP Gan To Kagaku Ryoho 23 1996 477 481
21. T. Taguchi, F. Tsukamoto, T. Watanabe, and et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer Gan To Kagaku Ryoho 26 1999 1163 1170
22. P.J. Hesketh Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting Cancer Investig. 18 2000 163 173
23. R.M. Navari, and J.M. Koeller Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine-3 receptor antagonists Ann. Pharmacother. 37 2003 1276 1286
24. World Health Organization Dolasetron mesylate and serious cardiovascular reactions WHO Drug Inf. 20 3 2006 185
25. U.S. Food and Drug Information FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) [online] Available from URL: http://www.fda.gov/Drugs.DrugSafety/usm237081.htm (Accessed 2010 Dec. 27)
26. Dolasetron [online] Available from URL: www.drugs.com/fda/dolasetron (Accessed 2012 July 27)
27. Ondansetron [online] Available from URL: www.drugs.com/fda/ondansetron (accessed 2012 July 27)
28. F. Roila, D. Warr, R. Clark-Snow, and et al. Delayed emesis: moderately emetogenic chemotherapy Support. Care Cancer 13 2 2005 104 108
29. O. Geling, and H. Eichler Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications J. Clin. Oncol. 23 2005 1289 1294
30. 3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial Lancet Oncol. 6 2005 765 772
31. M. Saito, K. Aogi, I. Sekine, and et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial Lancet Oncol. 10 2009 115 124
32. D.G. Warr, P.J. Hesketh, R.J. Gralla, and et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J. Clin. Oncol. 23 2005 2822 2830
33. A. Tuca Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review Cancer Manag. Res. 2 2010 1 12
34. R.V. Boccia, L.N. Gordan, G. Clark, and et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study Support. Care Cancer 19 2011 1609 1617
35. H. Raftopoulos, W. Cooper, Erin O'Boyle, and et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial Support. Care Cancer 23 2015 723 732
36. 3 receptor antagonist in vivo Br. J. Pharmacol. 114 1995 860 866
37. P. Eisenberg, F.R. MacKintosh, P. Ritch, and et al. Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study Ann. Oncol. 15 2004 330 337
38. 3 receptor internalization and causes prolonged inhibition of receptor function Eur. J. Pharmacol. 626 2010 193 199
39. C. Rojas, and B.S. Slusher Pharmacological mechanisms of 5-HT3 tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting Eur. J. Pharmacol. 684 2012 1 7
40. M. Stathis, C. Pietra, C. Rojas, and B.S. Slusher Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects Eur. J. Pharmacol. 689 2012 25 30
41. A.G. Thomas, M. Stathis, C. Rojas, and B.S. Slusher Netupitant and palonosetron trigger NK-1 receptor internalization in NG108-15 cells Exp. Brain Res. 232 8 2014 2337 2344
42. C. Rojas, M. Raje, T. Tsukamoto, and B.S. Slusher Molecular mechanisms of 5-HT3 and NK-1 receptor antagonists in prevention of emesis Eur. J. Pharmacol. 722 2014 26 37
43. P. Eisenberg, J. Figueroa-Vadillo, R. Zamora, and et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron Cancer 98 2003 2473 2482
44. R. Gralla, M. Lichinitser, S. Van der Vegt, and et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase II trial comparing single dose of palonosetron with ondansetron Ann. Oncol. 14 2003 1570 1577
45. M.S. Aapro, S.M. Grunberg, G.M. Manikhas, and et al. A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Oncol. 17 2006 1441 1449
46. M. Aapro, A. Fabi, F. Nole, and et al. Double-blind, randomized, controlled-study of the efficacy and tolerability of palonosetron plus dexamethasone for one day with or without dexamethasone on days two and three in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy Ann. Oncol. 21 2010 1083 1088
47. L. Celio, A. Denaro, F. Agustoni, and et al. Palonosetron plus one-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial J. Support. Oncol. 10 2012 65 71
48. R. Boccia, S. Grunberg, E. Franco-Gonzales, and et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase III trial. 21 Support. Care Cancer 2013 1453 1460
49. 3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis Support. Care Cancer 19 2011 823 832
50. L. Schwartzberg, S.Y. Barbour, G.R. Morrow, and et al. Pooled analysis of phase III studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting Support. Care Cancer 22 2014 469 477
51. M. Popovic, D.G. Warr, C. Deangelis, and et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systemic review and meta-analysis of randomized controlled trials Support. Care Cancer 22 2014 1685 1697
52. C. Yavas, U. Dogan, G. Yavas, and et al. Acute effect of palonosetron on electrocardiographic parameters in cancer patients; a prospective study Support. Care Cancer 20 2012 2343 2347
53. K. Aogi, H. Sakai, H. Yoshizawa, and et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy Support. Care Cancer 20 7 2012 1507 1514
54. F. Roila, E. Ballatori, B. Ruggeri, and et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: a randomized, double-blind study J. Clin. Oncol. 32 2014 5s (Suppl.; abstr 9503)
55. F.P. Bymaster, D. Calligaro, J. Falcone, and et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
56. 6 receptors by olanzapine Eur. J. Pharmacol. 430 2001 341 349
57. D.B. Allison, and D.E. Casey Antipsychotic-associated weight gain: a review of the literature J. Clin. Psychiatry 62 2001 22 31
58. A.S. Hale Olanzapine Br. J. Hosp. Med. 58 1997 443 445
59. L.E. Goldstein, J. Sporn, S. Brown, and et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment Psychosomatics 40 1999 438 443
60. C.M. Hocking, and G. Kichenadese Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review Support. Care Cancer 22 2014 1143 1151
61. N. Mizukami, M. Yamauchi, and K. Kazuhiko Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: A randomized, double-blind, placebo-controlled study J. Pain Symptom Manag. 47 2014 542 550
62. S.D. Passik, R.M. Navari, P.J. Loehrer, and et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy Cancer Investig. 22 2004 383 388
63. R.M. Navari, L.H. Einhorn, P.J. Loehrer, and et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting Support. Care Cancer 13 2005 529 534
64. R.M. Navari, L.H. Einhorn, P.J. Loehrer, and et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention for the prevention of chemotherapy-induced nausea and vomiting Support. Care Cancer 15 2007 1285 1291
65. R.M. Navari, C.K. Nagy, and S.E. Gray Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Support. Care Cancer 21 2013 1655 1663
66. M.G. Kris, P.J. Hesketh, M.R. Somerfield, and et al. American society of clinical oncology guidelines for antiemetics in oncology: update 2006 J. Clin. Oncol. 24 2006 2932 2947
67. B.L. Rapoport, K. Jordon, J.A. Boice, and et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapy and tumor types: a randomized, double-blind study Support. Care Cancer 18 2010 423 431
68. N. del Castillo, B.M. Zimmerman, B. Tyler, and et al. 759C/T variants of the serotonin (5HT2C) receptor gene and weight gain in children and adolescents in long-term risperidone treatment Clin. Pharmacol. Biopharm. 2 2013 110